Search tips
Search criteria 


Logo of bmjLink to Publisher's site
BMJ. 1999 November 27; 319(7222): 1414–1417.
PMCID: PMC1117144
Recent advances

Management of self poisoning

Alison L Jones, consultant physician and Glyn Volans, director


Around 15%-20% of the workload of medical units and 10% of the workload of accident and emergency departments in the United Kingdom are due to self poisoning.1,2 Episodes of self poisoning in the United Kingdom continue to rise, particularly in young men, and alcohol is often taken with the overdose.2 In general the severity of poisoning has diminished over the past 10 years with the introduction of safer drugs, such as newer serotonin reuptake inhibitors, but the total number of deaths from poisoning in the United Kingdom remains steady at 4000 per year, and the commonest cause of death by poisoning is carbon monoxide.2,3 This article highlights several specific advances in the management of poisoning over the past two or three years.


We searched Medline and Embase with the keywords “poisoning,” “intoxication,” “toxin,” and “overdose.” We included topics as a result of discussion with colleagues in clinical toxicology in the United Kingdom, Europe, Australia, and the United States.

New guidelines on gut decontamination

The American Academy of Clinical Toxicology and the European Association of Poisons Centres and Clinical Toxicologists have recently produced new guidelines on gut decontamination on the basis of consensus and evidence based statements.46 It is important to understand the advances in understanding and changes in practice that come from the guidelines, but the evidence base for them is limited.47

Activated charcoal

Activated charcoal should be given as a single dose (50 g for an adult, 1 g/kg body weight for a child up to 12 years) up to 1 hour after ingestion of a substantial amount of toxin.4 Beyond this time adsorption is reduced.4,8 What constitutes a substantial amount of toxin depends on the toxin but in general it is a dose expected to cause moderate to severe toxicity. The guidelines do not apply to agents for which multiple dose charcoal would be beneficial or for substances that are not readily adsorbed to charcoal (box (boxB1B1).4,5 Charcoal should never be given if the airway cannot be protected, as aspiration pneumonitis is a risk.9

Recent advances

  • In most cases of poisoning with a substantial amount of toxin the preferred method of gut decontamination is to give activated charcoal within 1 hour of ingestion
  • When a potentially lethal amount of a drug is not adsorbed by activated charcoal, such as iron or lithium tablets, whole bowel irrigation with polyethylene glycol solution is recommended
  • The role of hyperbaric oxygen in the treatment of carbon monoxide poisoning is controversial
  • 4-Methylpyrazole is a new antidote for the treatment of severe poisoning with methanol and ethylene glycol
  • Awareness of those at increased risk of paracetamol overdose should lead to appropriate administration of N-acetylcysteine
  • Ketamine (“special K”), gammahydroxybutyrate, and “sextasy” (ecstasy plus sidafenil) are recent drugs of misuse
  • Developments in databases have allowed doctors and nurses to access more information on management of poisoning with common substances
: Substances not readily adsorbed to charcoal

Multiple doses of activated charcoal (adults: 50 g immediately followed by 25 g every 2 hours or 50 g every 4 hours; children: 1 g/kg body weight followed by 1 g/kg body weight every 4 hours) should be considered for the adsorption and enhanced elimination of certain toxins (box (boxB2B2).5 The role of more than one dose of activated charcoal in salicylate poisoning remains controversial, but the current guideline states that single dose charcoal should be used up to 1 hour after ingestion.4,5

: Indications for multiple dose activated charcoal

Gastric lavage

Gastric lavage is only used up to 1 hour after ingestion of a substantial amount of toxin; many clinical toxicologists rarely use this method now.6 One study showed that gastric emptying by lavage and emesis failed to remove all the tablets taken by patients, and that a large residue often remained.10 An Australian study showed that outcome in poisoning was not improved by gastric lavage and activated charcoal versus activated charcoal alone; however, the number of patients that were seriously poisoned was comparatively small.11 Gastric lavage is absolutely contraindicated after ingestion of corrosive substances and comparatively contraindicated after ingestion of hydrocarbon solvents, such as white spirit, because of the risk of lipoid pneumonitis.6


Syrup of ipecacuanha is now rarely used as an emetic as there is no evidence that it decreases morbidity or mortality in poisoning. Additionally, emetics may increase morbidity by causing symptom free patients to become nauseated and to vomit.12 It is also difficult to give activated charcoal after an emetic.12

Whole bowel irrigation

In whole bowel irrigation a solution of polyethylene glycol is given orally or by nasogastric tube (2 litres per hour in adults) until the rectal effluent becomes clear (usually after 2-6 hours). It is contraindicated in patients with bowel obstruction, perforation, ileus, haemodynamic instability, or where the airway cannot be protected.13 Polyethylene glycol should be considered when patients have ingested potentially serious substances—for example, sustained release or enteric coated preparations. It is also of theoretical value after such ingestions of lithium, iron, arsenic, lead oxide, and zinc sulphate.13 Polyetheylene glycol or laxatives are sometimes used in body packers to remove packets that are beyond the pylorus, although one report described the death of a body packer when ingested condoms dissolved after paraffin was given.14 Packets in the stomach are best removed endoscopically, and packets in the small or large intestine that contain potentially lethal amounts of drugs should be removed surgically.15,16 The alternative is to wait for the packet to pass through the body naturally, which it is possible to do with less toxic drugs such as cannabis.

Carbon monoxide poisoning

Hyperbaric oxygen

Carbon monoxide causes severe hypoxia by forming carboxyhaemoglobin, which impairs oxygen delivery from blood to tissues and prevents the use of available oxygen by combining with cytochrome oxidase.17 Death may result from cardiac and neurological sequelae acutely but subacute and chronic exposure are also important. The scientific rationale for hyperbaric oxygen improving outcome in carbon monoxide poisoning is that the half life of carboxyhaemoglobin is reduced, and that the reduced amounts of carbon monoxide bind to the enzyme.17,18 To date, however, five randomised trials have disagreed on whether treatment with hyperbaric oxygen works in clinical practice.1923 Limitations to the trials were too few patients, inclusion of patients exposed to other toxins in fires, and different protocols for hyperbaric oxygen therapy. The latest study suggested that hyperbaric oxygen therapy might be harmful, but only 46% of patients attended follow up.23 The current recommendation is that hyperbaric oxygen therapy should be considered if a patient has been unconscious at any stage since exposure, if carboxyhaemoglobin concentrations have exceeded 40% at any time, or if there are neurological or psychiatric features. The logistical difficulties in transporting patients to hyperbaric oxygen chambers should not be underestimated.

Paracetamol poisoning

Paracetamol continues to generate the greatest number of emergency inquiries to the National Poisons Information Service of any single agent, and it constitutes 48% of hospital admissions for poisoning in the United Kingdom.24 A practical wall chart for management of paracetamol poisoning has been approved by physicians of the National Poisons Information Service, paediatricians, and accident and emergency clinicians.25

Patients at increased risk from paracetamol poisoning are those with enzyme induction such as patients taking anticonvulsants or those with glutathione depletion such as anorexic patients. Such patients should receive N-acetylcysteine at lower plasma paracetamol concentrations than patients at normal risk.2527 Defining those at risk is not new, but there is greater awareness both of who they are and of failure to provide appropriate antidotal treatment. The main message in paracetamol poisoning is “if in doubt, treat with N-acetylcysteine.” Anaphylactoid reactions occur in about 5% of patients given N-acetylcysteine, often within an hour of starting the infusion.28

Management difficulties in paracetamol poisoning include patients presenting 15 hours or more after ingestion of the drug or patients taking staggered overdoses—in excess of 150 mg/kg/day body weight or 12 g for an adult, whichever is the lesser. A poisons centre or a liver transplant unit should be contacted if there is evidence of hepatotoxicity or doubt about its management. This ensures that referral takes place before the criteria for liver transplantation are met (a prothrombin time greater than 100 seconds, serum creatinine concentration greater than 300 μmol/l, and grade III or IV encephalopathy or a pH of less than 7.3 at 24 hours or more after ingestion, after correction of hypovolaemia) and that intensive care support is appropriate.29 N-acetylcysteine is also used in patients with fulminant hepatic failure (encephalopathy and renal failure) due to paracetamol and it is not acting by glutathione repletion at this stage. N-acetylcysteine may scavenge free radicals or exert some haemodynamic effect, although its role is debatable.3032

Drugs of misuse


Drugs of misuse continue to present problems, particularly in inner city areas. Ecstasy (methylenedioxymethamphetamine or MDMA) causes dehydration with hyperthermia, agitation, and fits. Deaths still result from ecstasy poisoning. Treatments that may decrease mortality, particularly if the rectal temperature exceeds 40oC, include active cooling measures such as cool intravenous fluids, and use of the muscle relaxant dantrolene.33 The extent to which dantrolene is of value is, however, in doubt and it has dose dependent adverse effects such as hepatitis.33 Hepatotoxicity has occurred with ecstasy poisoning, and this has been treated with liver transplantation.34,35 Other features of ecstasy poisoning include hyponatraemia, cerebral infarction or haemorrhage due to uncontrolled hypertension, or vasculitis.35 Many substances are now added to ecstasy tablets such as caffeine and ketamine.36 Ketamine is a veterinary anaesthetic, which in man causes a dissociative state and has led to it being used for “date rapes.”36 Ketamine has also resulted in accidents as the drug causes pain free floating sensations with vivid dreams. A current vogue is the use of sidafenil (Viagra) with ecstasy for enhanced effects, so called sextasy.

Liquid Ecstasy

Another recent drug of misuse is gammahydroxybutyric acid (GHB or “liquid ecstasy”).37 The drug is dissolved in water to produce a clear liquid and is consumed until a “high” is reached.37 Liquid ecstasy increases intracerebral dopamine and if taken in excess causes drowsiness followed by seizures, hypoventilation, and loss of consciousness.37,38 The response is unpredictable, and coma and seizures have been produced by as little as 5 ml in an adult. Liquid ecstasy acts synergistically with ethanol to produce central nervous system and respiratory depression.37,38 Naloxone has been shown to reverse some of the effects of liquid ecstasy in animals, but its efficacy in man is unknown.38

Ethylene glycol and methanol poisoning

Poisoning with ethylene glycol and methanol have traditionally been treated by a combination of haemodialysis to remove toxic metabolites and ethanol to competitively inhibit enzymes responsible for production of the toxic metabolites. Like ethanol, 4-methylpyrazole is a competitive inhibitor of alcohol dehydrogenase, blocking the metabolism of ethylene glycol into its toxic metabolites glycolate and oxalate.39 4-Methylpyrazole is licensed for use in several countries, including the United States and United Kingdom, and is used to treat severe methanol or ethylene glycol poisoning. Compared with treatment with ethanol it has the advantage of reduced central nervous system depression, although haemodialysis may still be needed to remove accumulated metabolites and for the management of renal failure.39,40

Poisons databases

In the United Kingdom several databases have been developed to meet the increasing needs of doctors and nurses for information on poisons (box (boxB3).B3). In addition, easy internet access to a wide variety of sources of poisons information, including lethal “recipes,” enables people both to be better informed and to be at greater risk from serious poisoning.

: Poisons databases

Self poisoning is an important clinical problem, and several advances in recent years have been initiated by cases reports, which are then developed into multicentre—often multinational—collaborations. Information on the management of particularly unusual or serious cases can be obtained from the National Poisons Information Service.


We thank Ms Helaine Chesser, librarian at the Medical Toxicology Unit, for tracking references, and the staff of the National Poisons Information Service for comments and suggestions for this paper.


Competing interests: The Medical Toxicology Unit and GV have received funding from Cambridge Laboratories to support postgraduate teaching and training.


1. Greaves I, Goodacre S, Grout P. Management of drug overdose in accident and emergency departments in the United Kingdom. J Accident Emerg Med. 1996;13:46–48. [PMC free article] [PubMed]
2. Hawton K, Fagg J, Simkin S, Bale E, Bond A. Trends in deliberate self-harm in Oxford, 1985-1995—implications for clinical services and the prevention of suicide. Br J Psychiatry. 1997;171:556–560. [PubMed]
3. Wilson RC, Saunders PJ, Smith G. An epidemiological study of acute carbon monoxide poisoning in the West Midlands. Occup Env Med. 1998;55:723–728. [PMC free article] [PubMed]
4. American Academy of Clinical Toxicology and European Association of Poisons Centres. Position statement: single-dose activated charcoal. J Clin Toxicol-Clin Toxicol1997;35:721-41. [PubMed]
5. American Academy of Clinical Toxicology and European Association of Poisons Centres. Multiple-dose activated charcoal. J Clin Toxicol-Clin Toxicol(in press).
6. American Academy of Clinical Toxicology and European Association of Poisons Centres. Gastric lavage. J Clin Toxicol-Clin Toxicol. 1997;35:711–719. [PubMed]
7. Henry JA, Hoffman JR. Continuing controversy on gut decontamination. Lancet. 1998;352:420–421. [PubMed]
8. Neuvonen PJ, Vartiainen M, Tokola O. Comparison of activated charcoal and syrup of ipecacuanha in preventing drug absorption. Eur J Clin Pharmacol. 1983;24:557–562. [PubMed]
9. Menzies DG, Busuttil A, Prescott LF. Fatal pulmonary aspiration of oral activated charcoal. BMJ. 1988;297:459–460. [PMC free article] [PubMed]
10. Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study. J R Soc Med. 1991;84:35–38. [PMC free article] [PubMed]
11. Pond SM, Lewis-Driver DJ, Williams GM, Green AC, Stevenson NW. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust. 1995;163:345–349. [PubMed]
12. American Academy of Clinical Toxicology and European Association of Poisons Centres. Position statement: ipecac syrup. J Clin Toxicol-Clin Toxicol. 1997;35:699–709. [PubMed]
13. American Academy of Clinical Toxicology and European Association of Poisons Centres. Whole bowel irrigation. J Clin Toxicol-Clin Toxicol. 1997;35:753–762. [PubMed]
14. Visser L, Stricker B, Hoogendoorn M, Vinks A. Do not give paraffin to packers. Lancet. 1998;352:1352. [PubMed]
15. Lancashire MJR, Legg PK, Lowe M, Davidson SM, Ellis BW. Surgical aspects of international drug smuggling. BMJ. 1988;296:1035–1037. [PMC free article] [PubMed]
16. Choudhary AM, Taubin H, Gupta T, Roberts I. Endoscopic removal of a cocaine packet from the stomach. J Clin Gastroenterol. 1998;27:155–156. [PubMed]
17. Brown SD, Piantadossi CA. In vivo binding of carbon monoxide to cytochrome c oxidase in rat brain. J Appl Physiol. 1990;68:604–610. [PubMed]
18. Pace N, Strajman E, Walker EL. Acceleration of carbon monoxide elimination in man by high pressure oxygen. Science. 1950;111:652–654. [PubMed]
19. Ducasse JL, Celsius P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation? Undersea Hyperb Med. 1995;22:1–9. [PubMed]
20. Thom SR, Tber RL, Mendiguren II, Clark JM, Hardy KR, Fisher AB. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med. 1995;25:474–480. [PubMed]
21. Raphael J-C, Elkarrat D, Jars-Guincestre MC, Chastang C, Chasles V, Vercken JB, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet. 1989;ii:414–419. [PubMed]
22. Mathieu D, Wattel F, Mathieu-Nolf M. Randomized prospective study comparing the effect of HBO versus 12 hours NBO in non-comatose CO poisoned patients: results of the interim analysis. Undersea Hyperb Med. 1996;23:7–8. [PubMed]
23. Scheinkestel CD, Biley M, Myles PS, Jones K, Cooper DJ, Millar IL, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Med J Aust. 1999;170:203–210. [PubMed]
24. Hawton K, Ware C, Mistry H, Hewitt J, Kingsbury S, Roberts D, et al. Paracetamol self-poisoning. Characteristics, prevention and harm reduction. Br J Psychiatry. 1996;168:43–48. [PubMed]
25. Paracetamol Information Centre. Guidelines on the management of paracetamol poisoning. London: Paracetamol Information Centre; 1999.
26. Routledge PA, Vale JA, Bateman DN, Johnston GD, Jones AL, Judd A, et al. Paracetamol (acetaminophen) poisoning. BMJ. 1998;317:1609–1610. [PMC free article] [PubMed]
27. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ. 1979;2:1098–1100. [PMC free article] [PubMed]
28. Dawson AH, Henry DA, McEwen J. Adverse reactions to intravenous N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust. 1989;150:1329–1331. [PubMed]
29. O'Grady JG, Wendon J, Tan KC, Potter D, Cottam S, Cohen AT, et al. Liver transplantation after paracetamol overdose. BMJ. 1991;303:221–223. [PMC free article] [PubMed]
30. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of haemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852–1857. [PubMed]
31. Jones AL. Mechanism of action of N-acetylcysteine in acetaminophen poisoning. Clin Toxicol. 1998;36:277–285. [PubMed]
32. Walsh TS, Hopton P, Philips BJ, Mackenzie SJ, Lee A. The effect of N-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure. Hepatology. 1998;27:1332–1340. [PubMed]
33. Denborough MA, Hopkinson KC. Dantrolene and “ecstasy.” Med J Aust. 1997;166:165–166. [PubMed]
34. Jones AL, Simpson KJ. Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol. 1999;12:129–133. [PubMed]
35. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”) Lancet. 1992;340:384–387. [PubMed]
36. Winstock AR, King LA. Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy. BMJ. 1996;313:423–424. [PMC free article] [PubMed]
37. Bismuth C, Dally S, Borron SW. Chemical submission: GHB, benzodiazepines and other knock out drops. J Clin Toxicol-Clin Toxicol. 1997;35:595–598. [PubMed]
38. Louagie HK, Verstrate AG, De Soete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. Clin Toxicol. 1997;35:591–594. [PubMed]
39. Jacobsen D, McMartin K. Methylpyrazole—present status. J Toxicol-Clin Toxicol. 1996;34:379–381. [PubMed]
40. Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, et al. Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med. 1999;340:8832–8838. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group